-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Day One Biopharmaceutical, Maintains $32 Price Target

Benzinga·02/26/2025 15:47:03
Listen to the news
Wedbush analyst Robert Driscoll reiterates Day One Biopharmaceutical (NASDAQ:DAWN) with a Outperform and maintains $32 price target.